FOR IMMEDIATE RELEASE
April 22, 2009
Contact:
Christine Guilfoy
Office: (301) 634-7253
cguilfoy@the-aps.org
Celiac Disease Update on
Episode 20 of Life Lines Podcast
 BETHESDA,
Md. (April 22, 2009) — Three years ago, a group of Dutch researchers led by
Frits Koning published a study in the American Journal of Physiology
on an enzyme that appeared capable of providing an effective
treatment for celiac disease.
This study, published by The American Physiological
Society (www.the-aps.org/press),
showed that prolyl endoprotease (PEP), might break down gluten in the
stomach before it ever reached the small intestine, where it causes damage.
(One study estimated that 1 in 133 people in the
U.S. have celiac disease, an uncontrolled immune response to wheat gluten
and similar proteins of rye and barley.)
In Episode 20 of Life Lines, Dr. Koning
updates us on his research on PEP, which is now being tested clinically.
Please listen to this episode by clicking
here or by going to
www.lifelines.tv and clicking on Episode 20: Celiac Disease. The
interview begins at 02:45.
To read the
American Journal of Physiology-Gastrointestinal and Liver
Physiology study on PEP,
please click
here.
For more information, please
contact Christine Guilfoy at
cguilfoy@the-aps.org or at 301.634.7253.
***
Physiology
is the study of how molecules, cells, tissues and organs function to create
health or disease. The American Physiological Society (APS) has been an
integral part of this scientific discovery process since it was established
in 1887.
|
